Normal view MARC view ISBD view

Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention. [Review]

MedStar author(s):

Citation: Minerva Cardioangiologica. 60(1):95-100, 2012 Feb.PMID: 22322577Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Acute Coronary Syndrome/su [Surgery] | *Angioplasty, Balloon, Coronary | *Antithrombins/tu [Therapeutic Use] | *Heparin/tu [Therapeutic Use] | *Peptide Fragments/tu [Therapeutic Use] | *Platelet Glycoprotein GPIIb-IIIa Complex/ai [Antagonists & Inhibitors] | Angioplasty, Balloon, Coronary/ae [Adverse Effects] | Drug Therapy, Combination | Hirudins | Humans | Postoperative Complications/et [Etiology] | Postoperative Complications/pc [Prevention & Control] | Recombinant Proteins/tu [Therapeutic Use]ISSN:

0026-4725

Name of journal: Minerva cardioangiologicaAbstract: Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with "stable" angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.All authors: Mahmoudi M, Waksman RDate added to catalog: 2013-09-17

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article		Available		22322577

Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with "stable" angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.

English